WO2001080871A2 - Anwendung von guanylat-zyklase-c (gc-c) agonisten als insulinotrope faktoren zur behandlung von diabetes mellitus typ 2 - Google Patents
Anwendung von guanylat-zyklase-c (gc-c) agonisten als insulinotrope faktoren zur behandlung von diabetes mellitus typ 2 Download PDFInfo
- Publication number
- WO2001080871A2 WO2001080871A2 PCT/EP2001/004538 EP0104538W WO0180871A2 WO 2001080871 A2 WO2001080871 A2 WO 2001080871A2 EP 0104538 W EP0104538 W EP 0104538W WO 0180871 A2 WO0180871 A2 WO 0180871A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- agonists
- guanylin
- use according
- guanylate cyclase
- sequence
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Definitions
- guanylate cyclase-C guanylate cyclase-C (GC-C ⁇ a ⁇ onists as insulinotropic factors for the treatment of type 2 diabetes mellitus
- the invention relates to the use of guanylate cyclase-C (GC-C) agonists for the treatment of type 2 diabetes mellitus. According to the latest findings, the activation of GC-C of the pancreatic ⁇ -cell leads to an insulin release.
- GC-C guanylate cyclase-C
- the GC-C belongs to the family of membrane-bound guanylate cyclases, of which six different proteins (GC-A to GC-E) with different biological functions are known to date.
- GC-C The biological functions of GC-C include intestinal homeostasis (2). Activated by its endogenous ligands guanylin and uroguanylin or exogenous ligands such as STa, the GC-C synthesizes cytosolic cGMP. Chloride ions are secreted into the intestinal lumen via the cGMP-dependent protein kinase G and the CFTR chloride ion rectifier. This leads to an osmotically motivated dilution of the intestinal contents. Activation of the intestinal GC-C to a pathological extent leads to secretory diarrhea.
- the problem underlying the invention is to provide an insulinotropic drug.
- the problem is solved by a drug containing at least one agonist of the membrane-bound guanylate cyclases GC-C.
- these agonists can be used to produce an insulinotopic drug.
- GC-C agonists come in Question: Polypeptides with the sequence of the guanylin PGTCEICAYAACTGC and / or the uroguanylin with the sequence FKTLRTIANDDCELCVNVACTGCL as well as its biologically active fragments and / or derivatives, in particular amidated, acytelated, sulfated, phosphoryated, glycosylated and / or polyethylene derivative-modified derivate.
- polypeptides which have at least 90% sequence identity to the said guanylides and uroguanylid sequences.
- the medicaments according to the invention can also be given in combination with other medicaments.
- the GC-C agonists can in particular be formulated in preparations which are suitable for injection. Likewise, ointments, "slow release” capsules and similar galenic preparations can be used.
- guanylin and uroguanylin low-molecular substances which can be used as agonists of GC-C can also be used.
- agonists of GC-C to be used according to the invention are used in particular in amounts which show biological effectiveness.
- a corresponding dose range can easily be determined in biochemical assays. The corresponding dose can then be further specified in animal experiments.
- GC-C agonists to be used according to the invention can also be used to produce a medicament for the treatment of diabetes mellitus, in particular type 2.
- Figure 1 Guanylin 22-115 shows a similar high activity to INS-1 cells
- FIG. 3 The inhibitory effect of Rp-8-Br-PET-cGMPS is shown at concentrations of 1 ⁇ M only with the guanylin-dependent insulin release.
- FIG. 4 The guanylin-induced increase in cytosolic calcium levels can be completely inhibited by 1 ⁇ M Rp-8-Br-PET-cGMPS.
- Guanylin-dependent insulin secretion was demonstrated on the GC-C knock out model. In contrast to islands from wild-type mice, no response to the application of guanylin could be detected on isolated Langerhans ' islands. GC-C agonists thus release insulin from ß cells. Guanylin 22-115 and 101-115 are able to produce insulin release from a pancreatic b-cell line (INS-1) and from isolated Langerhans * mouse islets (FIG. 1). These effects are similar to the increase in insulin induced by glucose administration. Furthermore, they are additive to those induced by 18 mM glucose, the natural stimulus for insulin release (Fig. 2).
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2001256315A AU2001256315A1 (en) | 2000-04-22 | 2001-04-21 | Use of guanylate cyclase-c (gc-c) agonists as insulinotropic factors for treating diabetes type 2 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10020028.1 | 2000-04-22 | ||
DE10020028 | 2000-04-22 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001080871A2 true WO2001080871A2 (de) | 2001-11-01 |
WO2001080871A3 WO2001080871A3 (de) | 2002-04-04 |
Family
ID=7639744
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2001/004538 WO2001080871A2 (de) | 2000-04-22 | 2001-04-21 | Anwendung von guanylat-zyklase-c (gc-c) agonisten als insulinotrope faktoren zur behandlung von diabetes mellitus typ 2 |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2001256315A1 (de) |
WO (1) | WO2001080871A2 (de) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009039979A1 (en) * | 2007-09-11 | 2009-04-02 | Mondobiotech Laboratories Ag | Use of the peptide pro-gly-thr-cys-glu-ile-cys-ala-tyr-ala-ala-cys-thr-gly-cys as a therapeutic agent |
WO2011057272A1 (en) * | 2009-11-09 | 2011-05-12 | Ironwood Pharmaceuticals, Inc. | Treatments for gastrointestinal disorders |
US8735360B2 (en) | 2009-12-07 | 2014-05-27 | Ironwood Pharmaceuticals, Inc. | Treatments for gastrointestinal disorders |
US9303066B2 (en) | 2011-05-11 | 2016-04-05 | Ironwood Pharmaceuticals, Inc. | Treatments for gastrointestinal disorders |
US9527887B2 (en) | 2011-06-08 | 2016-12-27 | Ironwood Pharmaceutical, Inc. | Treatments for gastrointestinal disorders |
US9617305B2 (en) | 2011-06-08 | 2017-04-11 | Ironwood Pharmaceuticals, Inc. | Treatments for gastrointestinal disorders |
US9650417B2 (en) | 2011-05-11 | 2017-05-16 | Ironwood Pharmaceuticals, Inc. | Treatments for gastrointestinal disorders |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4309815A1 (de) * | 1993-03-26 | 1994-09-29 | Forssmann Wolf Georg | Verfahren zur Gewinnung und Anwendung des Guanylatzyklavaktivierenden Peptid I (GAP-I) |
DE19543628A1 (de) * | 1995-11-24 | 1997-05-28 | Forssmann Wolf Georg | Humanes, im Blut zirkulierendes Peptid mit insulinotroper Wirkung (GCAP-II-(89-112), (Guanylyl Cyclase C Aktivierendes Peptid II) und seine GCAP-Analoga, insbesondere das GCAP-I-(99-115), seine Anwendung als pharmakologischer Wirkstoff und Benutzung seines Wirkungsprinzipes zur Bereitstellung neuer GC-C-abhängiger insulinotroper Wirkstoffe |
WO1999014239A1 (de) * | 1997-09-12 | 1999-03-25 | Wolf Georg Forssmann | Zusammensetzung zur therapie von diabetes mellitus und fettsucht |
DE19744027A1 (de) * | 1997-10-06 | 1999-04-08 | Hoechst Marion Roussel De Gmbh | Substituierte Pyrazolo[3,4-b]pyridine, ihre Herstellung und Verwendung in Arzneimitteln |
-
2001
- 2001-04-21 AU AU2001256315A patent/AU2001256315A1/en not_active Abandoned
- 2001-04-21 WO PCT/EP2001/004538 patent/WO2001080871A2/de active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4309815A1 (de) * | 1993-03-26 | 1994-09-29 | Forssmann Wolf Georg | Verfahren zur Gewinnung und Anwendung des Guanylatzyklavaktivierenden Peptid I (GAP-I) |
DE19543628A1 (de) * | 1995-11-24 | 1997-05-28 | Forssmann Wolf Georg | Humanes, im Blut zirkulierendes Peptid mit insulinotroper Wirkung (GCAP-II-(89-112), (Guanylyl Cyclase C Aktivierendes Peptid II) und seine GCAP-Analoga, insbesondere das GCAP-I-(99-115), seine Anwendung als pharmakologischer Wirkstoff und Benutzung seines Wirkungsprinzipes zur Bereitstellung neuer GC-C-abhängiger insulinotroper Wirkstoffe |
WO1999014239A1 (de) * | 1997-09-12 | 1999-03-25 | Wolf Georg Forssmann | Zusammensetzung zur therapie von diabetes mellitus und fettsucht |
DE19744027A1 (de) * | 1997-10-06 | 1999-04-08 | Hoechst Marion Roussel De Gmbh | Substituierte Pyrazolo[3,4-b]pyridine, ihre Herstellung und Verwendung in Arzneimitteln |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009039979A1 (en) * | 2007-09-11 | 2009-04-02 | Mondobiotech Laboratories Ag | Use of the peptide pro-gly-thr-cys-glu-ile-cys-ala-tyr-ala-ala-cys-thr-gly-cys as a therapeutic agent |
AU2010314866B2 (en) * | 2009-11-09 | 2014-10-30 | Ironwood Pharmaceuticals, Inc. | Treatments for gastrointestinal disorders |
CN102812038A (zh) * | 2009-11-09 | 2012-12-05 | 硬木药品公司 | 胃肠道病症的治疗 |
JP2013510182A (ja) * | 2009-11-09 | 2013-03-21 | アイロンウッド ファーマシューティカルズ, インコーポレイテッド | 胃腸障害のための処置 |
US8507447B2 (en) | 2009-11-09 | 2013-08-13 | Ironwood Pharmaceuticals, Inc. | Treatments for gastrointestinal disorders |
WO2011057272A1 (en) * | 2009-11-09 | 2011-05-12 | Ironwood Pharmaceuticals, Inc. | Treatments for gastrointestinal disorders |
US8946158B2 (en) | 2009-11-09 | 2015-02-03 | Ironwood Pharmaceuticals, Inc. | Treatments of gastrointestinal disorders |
TWI482626B (zh) * | 2009-11-09 | 2015-05-01 | Ironwood Pharmaceuticals Inc | 胃腸道病症的治療 |
CN102812038B (zh) * | 2009-11-09 | 2016-05-18 | 硬木药品公司 | 胃肠道病症的治疗 |
US8735360B2 (en) | 2009-12-07 | 2014-05-27 | Ironwood Pharmaceuticals, Inc. | Treatments for gastrointestinal disorders |
US9303066B2 (en) | 2011-05-11 | 2016-04-05 | Ironwood Pharmaceuticals, Inc. | Treatments for gastrointestinal disorders |
US9650417B2 (en) | 2011-05-11 | 2017-05-16 | Ironwood Pharmaceuticals, Inc. | Treatments for gastrointestinal disorders |
US9527887B2 (en) | 2011-06-08 | 2016-12-27 | Ironwood Pharmaceutical, Inc. | Treatments for gastrointestinal disorders |
US9617305B2 (en) | 2011-06-08 | 2017-04-11 | Ironwood Pharmaceuticals, Inc. | Treatments for gastrointestinal disorders |
Also Published As
Publication number | Publication date |
---|---|
AU2001256315A1 (en) | 2001-11-07 |
WO2001080871A3 (de) | 2002-04-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60116352T2 (de) | Verwendung von kcnq kaliumkanalagonisten zur herstellung eines arzneimittels zur modulierung der blasenfunktion | |
DE69627963T2 (de) | Verbesserte zusammensetzungen und verfahren zur chemodenervation mit neurotoxinen | |
DE69909794T2 (de) | Verwendung eines dipeptids für wiederherstellungsprozesse | |
DE3249683C2 (de) | Verfahren zur Herstellung eines Verbundstoffs mit Langzeit-Freigabe | |
DE3528979C2 (de) | ||
EP0857064B1 (de) | Stabilisierte schilddrüsenhormonhaltige arzneimittel | |
DE19740733A1 (de) | Pharmazeutische Zubereitungen für die intranasale Verabreichung | |
DE2415101A1 (de) | Pharmazeutische zusammensetzungen | |
DE10154689A1 (de) | Substituierte Aminoketonverbindungen | |
EP1003786A1 (de) | Peptid mit radioprotektiver wirkung | |
DE112013001457T5 (de) | Transdermales Applikationssystem | |
EP0185210B1 (de) | Verwendung von Dipeptidderivaten für die Herstellung von Arzneimitteln zur Behandlung von an amyotropher Lateralsklerose Erkrankten | |
WO2001080871A2 (de) | Anwendung von guanylat-zyklase-c (gc-c) agonisten als insulinotrope faktoren zur behandlung von diabetes mellitus typ 2 | |
DE3510654A1 (de) | Neue pharmazeutische anwendung von cgrps | |
EP0438756B1 (de) | Cytostatische und cytotoxische Wirkstoffkombination zur Anwendung in therapeutischen Verfahren | |
DE69722809T2 (de) | Behandlung von stressinduzierten hautkrankheiten unter verwendung von corticoliberin (crh)-antagonisten und inhibitoren der hautmastzell-degranulation | |
DE60124915T2 (de) | Synthetische peptide gegen neurologische krankheiten | |
DE102004051014A1 (de) | Chemisch modifizierte Peptidanaloga | |
DE69930150T2 (de) | Arginin-reiche anti-vaskuläre endotheliale wachstumsfaktor-peptide,welche wachstum und metastase humaner tumorzellen durch blockierung der angiogenese inhibieren | |
EP0398165A1 (de) | Kombinationspräparate enthaltend Rifampicin und Thioacetazon sowie gegebenenfalls Isonicotinsäurehydrazid oder Ethambutol als aktive Wirkstoffe | |
DE10053506A1 (de) | Mittel zur Prävention von Organschäden, die durch Aminoglykoside induziert werden | |
DE10228680A1 (de) | Grundlage für transdermale Formulierungen (PTF) | |
DE60220799T2 (de) | Hypoglykämisches mittel | |
CH641680A5 (de) | Verfahren zur herstellung injizierbarer insulinpraeparate. | |
DE3737274A1 (de) | Verwendung von reinem h2a- und/oder h2b-histon als wirksubstanz zur herstellung von arzneimitteln |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |